Damora Therapeutics Completes Cayman Islands Redomestication
I'm LongbridgeAI, I can summarize articles.Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026. Shareholders approved the plan in February 2026. Existing shares automatically converted to Cayman ordinary and preferred shares without shareholder action. The company's business, management, assets, liabilities, and Nasdaq listing (DMRA) remain unchanged, except for a new CUSIP and updated indemnification agreements.
Damora Therapeutics ( (DMRA) ) has provided an update.
On February 9, 2026, Damora Therapeutics’ stockholders approved a plan to redomesticate the company from Delaware to the Cayman Islands, a move that became effective on July 16, 2026. Under this plan of conversion, the company filed the necessary corporate documents in both jurisdictions and established Cayman law governance through new memorandum, articles of association, and preferred share designations.
As part of the redomestication, each share of common and preferred stock of the Delaware entity automatically converted into corresponding ordinary and preferred shares of the Cayman company, with no action required from shareholders. The company emphasized that its business, management, contractual obligations, assets, liabilities, and Nasdaq listing under the ticker DMRA remain unchanged, aside from a new CUSIP and updated indemnification agreements for directors and officers to support the new corporate structure.
The most recent analyst rating on (DMRA) stock is a Buy
with a $40.00 price target.
To see the full list of analyst forecasts on Damora Therapeutics stock,
see the DMRA Stock Forecast page.
Spark’s Take on DMRA Stock
According to Spark, TipRanks’ AI Analyst, DMRA is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, large and widening losses, and ongoing cash burn despite some improvement in 2025 cash outflow). Technicals are neutral and do not provide a strong offset, while valuation is also pressured by a negative P/E and lack of dividend support.
To see Spark’s full report on DMRA stock,
click here.
More about Damora Therapeutics
Damora Therapeutics, Inc. is a biotechnology company focused on redefining care for patients with hematologic and blood disorders. The company is advancing next-generation biologics targeting mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, aiming to deliver disease-modifying treatments to address significant unmet medical need.
With multiple programs positioned as potential best-in-class therapies and scheduled to enter clinical development in 2026, Damora’s strategy emphasizes broad mutation coverage and convenient treatment modalities. The company’s ordinary shares trade on Nasdaq under the symbol DMRA, giving it continued access to public capital markets as it progresses its pipeline.
Average Trading Volume: 556,831
Technical Sentiment Signal: Buy
Current Market Cap: $1.94B
For an in-depth examination of DMRA stock, go to TipRanks’ Overview page.